Anteris Technologies Ltd is a publicly listed company on the Australian Securities Exchange under the ASX code AVR
AVR: A$0.00
0 (0%)
17:44 3rd Aug 2021 AEDT
2020 Annual Report
Investor Centre
Investor News
Why Invest?
The FDA approval of Transcatheter Aortic Valve Replacement (TAVR) in the treatment of low-risk (younger patients) is driving rapid market expansion. Today we have
With TAVR now being the treatment of choice for Aortic Stenosis patients, coupled with existing Transcatheter Heart Valves failing as early as five to eight years after implantation, then now is
At Anteris we bring
The inspiration for our DurAVR™ heart valves* stemmed from multiple conversations with interventional cardiologists, who reiterated that valve durability and repeat replacements were posing a large risk to patient health.
The proven benefits of our ADAPT® tissue paired with the unique design of DurAVR™ our 3D single-piece aortic valve, answers the need to
At Anteris we are committed in delivering durable solutions through our Better Science & Better Design that help healthcare professionals create life-changing outcomes for patients.
ASX Announcements
Financial Reports
Research Reports
- MST Access - AVR Update Report - May 21View
- MST Access - Q4 Results: Fresh Funds Available, Trials Progressing WellView
- Bioshares November 2020 ReportView
- MST Access - Initiation of Coverage October 2020View
- Bioshares July 2020 ReportView
- ABID June 2020 ReportView
- Bioshares June 2020 ReportView
- NDF Research - ADAPTing to market opportunitiesView
Annual General Meetings
Share Registry
Level 1, 200 Mary Street
Brisbane, QLD 4000
T 1300 850 505 (within Australia)
T +61 3 9415 4000 (outside Australia)
F 1800 783 447 (within Australia)
F +61 3 9473 2555 (outside Australia)